Genomic testing for localized prostate cancer: where do we go from here?

Stacy Loeb, Ashley E. Ross

Research output: Contribution to journalReview article

Abstract

Purpose of review The goal of this article is to discuss current genomic testing options in localized prostate cancer. Recent findings There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. Summary The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.

Original languageEnglish (US)
Pages (from-to)495-499
Number of pages5
JournalCurrent Opinion in Urology
Volume27
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Prostatic Neoplasms
Prostatectomy
Biopsy
Radiation Tolerance
Cell Lineage
Disease Progression
Prostate
Cell Cycle
Genome
RNA
Neoplasm Metastasis
Therapeutics

Keywords

  • Decipher
  • markers
  • OncotypeDx
  • Prolaris
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Genomic testing for localized prostate cancer : where do we go from here? / Loeb, Stacy; Ross, Ashley E.

In: Current Opinion in Urology, Vol. 27, No. 5, 01.09.2017, p. 495-499.

Research output: Contribution to journalReview article

Loeb, Stacy ; Ross, Ashley E. / Genomic testing for localized prostate cancer : where do we go from here?. In: Current Opinion in Urology. 2017 ; Vol. 27, No. 5. pp. 495-499.
@article{8035e120cb9d402c8ab05e5f53a4a5cd,
title = "Genomic testing for localized prostate cancer: where do we go from here?",
abstract = "Purpose of review The goal of this article is to discuss current genomic testing options in localized prostate cancer. Recent findings There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. Summary The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.",
keywords = "Decipher, markers, OncotypeDx, Prolaris, prostate cancer",
author = "Stacy Loeb and Ross, {Ashley E.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MOU.0000000000000419",
language = "English (US)",
volume = "27",
pages = "495--499",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Genomic testing for localized prostate cancer

T2 - where do we go from here?

AU - Loeb, Stacy

AU - Ross, Ashley E.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of review The goal of this article is to discuss current genomic testing options in localized prostate cancer. Recent findings There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. Summary The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.

AB - Purpose of review The goal of this article is to discuss current genomic testing options in localized prostate cancer. Recent findings There are multiple genomic tests currently available for men with localized prostate cancer. Prolaris, OncotypeDx, and Decipher can all be tested using biopsy tissue. Prolaris and Decipher are also available for men undergoing radical prostatectomy to predict subsequent disease progression. Summary The Prolaris cell cycle progression score measured on biopsy predicts the risk of prostate cancer death in 10 years with conservative management, whereas, the primary endpoint for the OncotypeDx genomic prostate score is the risk of adverse disease at radical prostatectomy. Decipher measures genome-wide RNA expression, and its Genomic Classifier signature was initially designed to predict the risk of metastasis for men with adverse disease at radical prostatectomy, and more recently, a biopsy version was released. Recently, Decipher signatures predicting prostate cancer cell lineage and postoperative radiation sensitivity have also been described. Any of these tests can be used by men with localized prostate cancer to provide additional prognostic risk stratification to aid in treatment decisions.

KW - Decipher

KW - markers

KW - OncotypeDx

KW - Prolaris

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85021664445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021664445&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000419

DO - 10.1097/MOU.0000000000000419

M3 - Review article

C2 - 28661898

AN - SCOPUS:85021664445

VL - 27

SP - 495

EP - 499

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -